Filtered By:
Specialty: Internal Medicine
Condition: Ischemic Stroke

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 1488 results found since Jan 2013.

Transient unilateral weakness: is it a transient ischaemic attack?
This article highlights the diagnostic challenges in transient ischaemic attack with relevance to unilateral weakness.PMID:36454061 | DOI:10.12968/hmed.2022.0414
Source: British Journal of Hospital Medicine - December 1, 2022 Category: Internal Medicine Authors: Charles C Southey Jonathan Birns Peter Sommerville Ajay Bhalla Source Type: research

A clinical application study of a stent placement assessment
Discussion: Currently, no prospective controlled data exist regarding the efficacy and safety of carotid stenting in the acute phase. Previously, we had developed an ECASES stent placement system for acute carotid artery occlusion. The present study will evaluate the efficacy and safety of ECASES in a randomized, double-blind prospective study and clarify its guiding significance in acute atherosclerotic carotid artery occlusion surgery.
Source: Medicine - November 25, 2022 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

The efficacy of heart rate variability biofeedback in patients with acute ischemic stroke: A protocol for systematic review and meta-analysis
Conclusion: HRV biofeedback may be a promising intervention for improving autonomic function, cognitive impairment, and psychological distress in patients with acute ischemic stroke.
Source: Medicine - November 18, 2022 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Ischemic Stroke in Patients With Malignancy
Approximately one-quarter to one-third of patients with ischemic stroke have an embolic stroke of undetermined source (ESUS). An estimated 5% to 10% of patients with ESUS have an active cancer diagnosis. Presence of cancer potentially increases the risk of acute ischemic stroke through various mechanisms such as cancer-related hypercoagulability, intracranial tumors leading to an arterial compression, or intracardiac tumors leading to cardioembolism. Certain cancer therapeutics can also contribute to risk of ischemic stroke.
Source: Mayo Clinic Proceedings - November 1, 2022 Category: Internal Medicine Authors: Ugur Sener, Zafer Keser Tags: Concise review Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among < em > CYP2C19 < /em > Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial
CONCLUSION: Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin.PRIMARY FUNDING SOURCE: Ministry of Science and Technology of the People's Republic of China.PMID:36315949 | DOI:10.7326/M22-1667
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anxin Wang Xuewei Xie Xue Tian S Claiborne Johnston Hao Li Philip M Bath Yingting Zuo Jing Jing Jinxi Lin Yilong Wang Xingquan Zhao Zixiao Li Yong Jiang Liping Liu Xia Meng Yongjun Wang Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among < em > CYP2C19 < /em > Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial
CONCLUSION: Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin.PRIMARY FUNDING SOURCE: Ministry of Science and Technology of the People's Republic of China.PMID:36315949 | DOI:10.7326/M22-1667
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anxin Wang Xuewei Xie Xue Tian S Claiborne Johnston Hao Li Philip M Bath Yingting Zuo Jing Jing Jinxi Lin Yilong Wang Xingquan Zhao Zixiao Li Yong Jiang Liping Liu Xia Meng Yongjun Wang Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research